Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Up 4,114.3% in December

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 39,109 shares, an increase of 4,114.3% from the November 30th total of 928 shares. Approximately 4.0% of the shares of the stock are sold short. Based on an average trading volume of 189,317 shares, the days-to-cover ratio is presently 0.2 days. Based on an average trading volume of 189,317 shares, the days-to-cover ratio is presently 0.2 days. Approximately 4.0% of the shares of the stock are sold short.

Analyst Ratings Changes

Several research analysts have commented on the company. HC Wainwright cut shares of Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $55.00.

Insider Activity

In other news, major shareholder James Peyer sold 3,507 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $7.96, for a total transaction of $27,915.72. Following the completion of the sale, the insider owned 155,142 shares of the company’s stock, valued at approximately $1,234,930.32. This represents a 2.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders sold 27,907 shares of company stock worth $287,280. Corporate insiders own 23.20% of the company’s stock.

Sensei Biotherapeutics Trading Up 0.6%

Shares of SNSE opened at $9.27 on Friday. The firm’s fifty day simple moving average is $9.19 and its two-hundred day simple moving average is $8.80. Sensei Biotherapeutics has a 12 month low of $5.00 and a 12 month high of $18.35. The stock has a market capitalization of $11.68 million, a P/E ratio of -0.48 and a beta of 0.32.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its earnings results on Friday, November 14th. The company reported ($3.62) EPS for the quarter, beating the consensus estimate of ($4.11) by $0.49. As a group, research analysts predict that Sensei Biotherapeutics will post -1.17 EPS for the current fiscal year.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.